This presentation is the intellectual property of the author.Contact them for permission to reprint and/or distribute.
Oral Anticoagulationin Patients with Atrial Fibrillation
and End Stage Renal Disease
Manoj M. Panday, M.D.Head, Section of Cardiac Electrophysiology
Division of CardiologyUT Health San Antonio
Disclosures
• Current consultant agreements with Janssen, Pfizer, Bristol Myers Squibb, Daiichi Sankyo, and Abbott
• Prior consultant agreements with Sanofi-Aventis, Medtronic, Boston Scientific, and Biotronik
This presentation is the intellectual property of the author.Contact them for permission to reprint and/or distribute.
Objectives
• Provide a concise review of the indications for thromboembolism prophylaxis in atrial fibrillation
• Discuss the pros and cons of using oral anticoagulation in patients with end stage renal disease
• Provide an overview of the treatment options in patients with atrial fibrillation who are on dialysis
Definition
“AF is a supraventricular tachyarrhythmia characterized by uncoordinated atrial activation with consequent deterioration of atrial mechanical function.”
Bellet. Clinical Disorders of the Heart Beat. 1971.
AF is characterized by rapid fibrillatory waves that vary in amplitude, shape, and timing, associated with an irregular ventricular response.
Fuster et al. ACC/AHA/ESC Atrial Fibrillation Guidelines. 2006.
This presentation is the intellectual property of the author.Contact them for permission to reprint and/or distribute.
Age-Specific Prevalence
Feinberg et al. Prevalence, Age Distribution, and Gender ofPatients with Atrial Fibrillation. Arch Intern Med 1995.
Natural Time Course of AF
ESC Guidelines. European Heart Journal. 2010;31:2369-2429.
This presentation is the intellectual property of the author.Contact them for permission to reprint and/or distribute.
Coumadin Clinics23+ million visits
Primary Care Providers
AfibPatients
3.2 millionCardiologists
Emergency Room Strokes/TIAs
NeurologistsStrokes (15%)
Electrophysiologists
CT SurgeonsSleep ClinicsOSA (50%)
Geriatrics
Spectrum of Health Care Professionals
2014 Atrial Fibrillation Guideline
This presentation is the intellectual property of the author.Contact them for permission to reprint and/or distribute.
AF Definitions: A Simplified Scheme
Term Definition
Paroxysmal AF • AF that terminates spontaneously or with intervention within 7 days of onset
Persistent AF • Continuous AF that is sustained for > 7 days
Longstanding persistent AF • Continuous AF of > 12 months duration
Permanent AF • Used when there has been a joint decision by the patient and clinician to cease further attempts to restore and/or maintain SR
• Acceptance of AF represents a therapeutic attitude on the part of the patient and clinician rather than a pathophysiological attribute of the AF
Nonvalvular AF • AF in the absence of rheumatic mitral stenosis, a mechanical or bioprosthetic heart valve, or mitral valve repair
2014 AHA/ACC/HRS Atrial Fibrillation Guideline.
Selected Risk Factors for AF
• Increasing age
• Hypertension
• Diabetes mellitus
• MI
• Valvular HD
• HF
• Obesity
• Obstructive sleep apnea
• Chronic kidney disease
• Cardiothoracic surgery
• Smoking
• Alcohol use
• Hyperthyroidism
• Increased pulse pressure
• European ancestry
• Family history
• Genetic variants
• LVH
• LA enlargement
• Increased CRP
• Increased BNP
This presentation is the intellectual property of the author.Contact them for permission to reprint and/or distribute.
Diet and Clinical Risk• Alcohol
– Consistently increased risk of AF in heavy alcohol drinkers, but no risk associated with moderate alcohol intake
• Caffeine– High coffee intake was not clearly associated with an increased
risk of AF, and a potential lower AF risk in moderate drinkers could exist
• Fish-derived n-3 polyunsaturated fatty acids– High intake from diet or supplements might prevent AF episodes
following cardiovascular events, but no consistent evidence supports an effect in primary prevention
• Ascorbic acid– Oral doses pre and post-CABG reduced AF occurrence from
25% to 4% compared to beta-blockers alone
Gronroos and Alonso. Diet and Risk of Atrial Fibrillation –Epidemiologic and Clinical Evidence. Circ J 2010 Oct.
Dietary Exposures and Pathophysiology
Gronroos and Alonso. Diet and Risk of Atrial Fibrillation –Epidemiologic and Clinical Evidence. Circ J 2010 Oct.
This presentation is the intellectual property of the author.Contact them for permission to reprint and/or distribute.
Mechanisms of Atrial Fibrillation
2014 AHA/ACC/HRS Atrial Fibrillation Guideline.
Clinical Case
• 76 yo female with CHF, HTN, DM, ESRD on HD, prior CVA, and CAD
• Patient had a major GIB requiring blood transfusion while in therapeutic range on warfarin
• She had a recurrent GIB on a NOAC
• She has a history of unsteady gait and prior falls
This presentation is the intellectual property of the author.Contact them for permission to reprint and/or distribute.
Keskar et al. ClinJ Am SocNephrol. 11: 2085-2092, 2016.
CHADS2 versus CHA2DS2-VASc Score
CHA2DS2-VASc Score
Congestive HF 1
Hypertension 1
Age ≥ 75 2
Diabetes 1
Stroke/TIA/TE 2
Vascular disease (prior MI, PAD, or aortic plaque)
1
Age 65-74 years 1
Sex category (female) 1
Maximum score 9
CHADS2 Score
Congestive HF 1
Hypertension 1
Age ≥ 75 1
Diabetes 1
Stroke/TIA/TE 2
Maximum score 6
This presentation is the intellectual property of the author.Contact them for permission to reprint and/or distribute.
CHADS2 versus CHA2DS2-VASc Score
CHA2DS2-VASc Score
Congestive HF 1
Hypertension 1
Age ≥ 75 2
Diabetes 1
Stroke/TIA/TE 2
Vascular disease (prior MI, PAD, or aortic plaque)
1
Age 65-74 years 1
Sex category (female) 1
Maximum score 9
CHADS2 Score
Congestive HF 1
Hypertension 1
Age ≥ 75 1
Diabetes 1
Stroke/TIA/TE 2
Maximum score 6
Our patient: CHA2DS2-VASc score = 9!
Stroke Risk Stratification
CHADS2Score
Adjusted stroke rate(% per year)
0 1.9
1 2.8
2 4.0
3 5.9
4 8.5
5 12.5
6 18.2
CHA2DS2-VAScScore
Adjusted stroke rate(% per year)
0 0
1 1.3
2 2.2
3 3.2
4 4.0
5 6.7
6 9.8
7 9.6
8 6.7
9 15.2
Gage et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001;285:2864-70. Lip et al. Atrial fibrillation. Lancet.
2012;379:648-61.
This presentation is the intellectual property of the author.Contact them for permission to reprint and/or distribute.
HAS-BLED Bleeding Risk Score
*Hypertension is defined as systolic blood pressure > 160 mmHg.
HAS-BLED Bleeding Risk Score
*Hypertension is defined as systolic blood pressure > 160 mmHg.
Our patient: HAS-BLED score = 5
This presentation is the intellectual property of the author.Contact them for permission to reprint and/or distribute.
Thromboembolism Prophylaxis
Left Atrial Thrombus
LA Thrombus Video.avi
This presentation is the intellectual property of the author.Contact them for permission to reprint and/or distribute.
Risk of Thromboembolism
• AF conveys a 5-fold increase in stroke risk compared with the general population
• 90% of the thrombi found in nonvalvularAF patients and 57% found in valvular AF are in the LAA
This presentation is the intellectual property of the author.Contact them for permission to reprint and/or distribute.
This presentation is the intellectual property of the author.Contact them for permission to reprint and/or distribute.
Medication Options for Thromboembolism
Prophylaxis
Vitamin K Antagonist – Warfarin
This presentation is the intellectual property of the author.Contact them for permission to reprint and/or distribute.
Warfarin Therapy
• Subtherapeutic INR levels (< 2.0) raised the incidence of stroke (RR: 2.39) and arterial thromboembolism (RR: 5.68) compared with therapeutic INR levels.
• Supratherapeutic INR levels (> 3.0) doubled the incidence of intracranial hemorrhage (RR: 2.11).
Walker and Bennett. Epidemiology and Outcomes in Patientswith Atrial Fibrillation in the US. Heart Rhythm 2008 Oct.
Stroke vs. Bleeding with Warfarin Therapy
Hylek and Singer. Risk Factors for Intracranial Hemorrhage in Outpatients Taking Warfarin. Ann Intern Med 1994. Data from Odén et al. Optimal INR for Prevention of
Stroke and Death in Atrial Fibrillation: A Critical Appraisal. Thromb Res 2006.
This presentation is the intellectual property of the author.Contact them for permission to reprint and/or distribute.
Aspirin Plus Clopidogrel
• ACTIVE-W (AF Clopidogrel Trial with Irbesartan for Prevention of Vascular Events)
– Primary endpoint of stroke, systemic embolism, MI, or vascular death in patients with an average of two risk factors
– 3.93% annual risk with warfarin and 5.60% with aspirin + clopidogrel (RR = 1.44, P = 0.0003)
– Rates of hemorrhage were similar between two groups– Significantly greater minor and total bleeds with aspirin + clopidogrel
Aspirin Plus Clopidogrel
• ACTIVE-A (Effect of Clopidogrel Added to Aspirin in Patients with Atrial Fibrillation)
– For patients who were deemed unsuitable for warfarin due to specific risk of bleeding, patient preference, or physician preference
– Similar primary endpoint to ACTIVE-W– 3.6 year average follow-up– 6.8% annual risk with aspirin + clopidogrel and 7.6% with aspirin + placebo (RR
= 0.89, P = 0.01)– Difference was primarily due to reduction of stroke by clopidogrel (2.4% versus
3.3%, RR = 0.72, P < 0.001)– Major bleeding occurred in 2.0% with aspirin + clopidogrel versus 1.3% with
aspirin + placebo (RR = 1.57, P < 0.001)
This presentation is the intellectual property of the author.Contact them for permission to reprint and/or distribute.
Aspirin Plus Clopidogrel
2011 Focused Update Recommendations
Class IIb (Level of evidence B)
The addition of clopidogrel to aspirin to reduce the risk of major vascular events, including stroke, might be
considered in patients with AF in whom oral anticoagulation with warfarin is considered unsuitable due to patient
preference or the physician’s assessment of the patient’s ability to safely sustain anticoagulation.
Wann et al. 2011 ACCF/AHA/HRS Focused Update on the Guidelines for the Management of Patients with AF.
RivaroxabanApixabanEdoxaban
Dabigatran
This presentation is the intellectual property of the author.Contact them for permission to reprint and/or distribute.
Coagulation Cascade
De Caterina et al. JACC. Vol. 59, No. 16, 2012.
McCullough et al. Clin J Am SocNephrol. 11: 2079-2084, 2016.
This presentation is the intellectual property of the author.Contact them for permission to reprint and/or distribute.
This presentation is the intellectual property of the author.Contact them for permission to reprint and/or distribute.
Dabigatran (RE-LY)
RE-LY (Randomized Evaluation of Long term anticoagulant therapY) trial was a prospective, randomized, open-label clinical phase III trial.
Comparing 2 blinded doses of dabigatranetexilate (110 mg B.I.D. [D110] or 150 mg B.I.D. [D150]) with open-label, adjusted-dose warfarin aiming for a target international normalized ratio (INR) of 2.0 to 3.0
Dabigatran (RE-LY)
A total of 18,113 patients with NVAF and at least one risk factor for stroke were included.
Patients with a stroke during the last 14 days or with a CrCl of 30 mL/min were excluded.
The mean CHADS2 score was 2.1, and 31.9% of the patients had a CHADS2 score of 0 to 1, 35.6% had a score of 2, and 32.5% had a score of 3 to 6.
Median treatment duration was 2 years.
This presentation is the intellectual property of the author.Contact them for permission to reprint and/or distribute.
Dabigatran (RE-LY)
The results showed a reduction of the primary outcome of stroke or systemic embolism from 1.71% in the warfarin group to 1.54% per year in the D110 group (HR = 0.90; 95% CI = 0.74 to 1.10; p = 0.001 for non-inferiority).
There was a reduction of 1.11% per year in the D150 group (HR = 0.65; 95% CI = 0.52 to 0.81; p = 0.001 for superiority).
Dabigatran (RE-LY)
The rate of major bleeding was 3.57% per year in the warfarin group compared with 2.87% per year in the D110 group (p = 0.003) and 3.32% in the D150 group (p = 0.31).
Rates of hemorrhagic stroke and intracranial bleeding were lower with both doses of dabigatran (annual intracranial bleeding rate = 0.1% with both D110 and D150 vs. 0.4% with warfarin; p = 0.001).
This presentation is the intellectual property of the author.Contact them for permission to reprint and/or distribute.
Dabigatran (RE-LY)
• Gastrointestinal bleeding, however, was increased from 1.0% per year on warfarin to 1.5% per year with the D150 group (p = 0.001).
• The rates of discontinuation at 2 years were higher with D150 (20.7%) and D110 (21.2%) than with warfarin (16.6%).
This presentation is the intellectual property of the author.Contact them for permission to reprint and/or distribute.
Rivaroxaban (ROCKET-AF)
Annual rate of major bleeding was 3.60% in the rivaroxaban group and 3.45% in the warfarin group (p = 0.58).
There was a lower rate of intracranial bleeding (0.5%/year vs. 0.7%/year; p = 0.02) and fewer fatal bleeding events (0.2%/year vs. 0.5%/year; p = 0.003) with rivaroxaban.
More patients with bleeding that required transfusion and more GI bleeding with rivaroxaban.
Apixaban (ARISTOTLE)
18,201 patients
Apixaban 5 mg bid versus warfarin
Primary efficacy endpoint: stroke and systemic embolism
Primary safety endpoint: major bleeding
Key secondary endpoint: all-cause mortality
Median age 70
Mean CHADS2 score = 2.1
This presentation is the intellectual property of the author.Contact them for permission to reprint and/or distribute.
Apixaban (ARISTOTLE)
Treatment discontinuation of 1.7% with apixaban versus 2.5% with warfarin
21% RRR of stroke and systemic embolism versus warfarin
31% RRR of major bleeding events versus warfarin
11% RRR in all-cause mortality versus warfarin
McCullough et al. Clin J Am SocNephrol. 11: 2079-2084, 2016.
This presentation is the intellectual property of the author.Contact them for permission to reprint and/or distribute.
Rivaroxaban (ROCKET AF)
• Included patients with nonvalvular atrial fibrillation at high risk of stroke.
• Randomized 14,264 patients to double-blind treatment with rivaroxaban 20 mg QD (15 mg daily for CrCl of 30 to 50 ml/min) or warfarin.
• Mean CHADS2 score of 3.5.
This presentation is the intellectual property of the author.Contact them for permission to reprint and/or distribute.
Rivaroxaban (ROCKET AF)
55% had a history of stroke, TIA, or systemic embolism.
The warfarin treatment aimed at an INR level between 2.0 and 3.0. The mean time in therapeutic range was 55% (median 58%).
Primary objective was to demonstrate non-inferiority versus warfarin for the occurrence of stroke or systemic embolism.
Rivaroxaban (ROCKET AF)
• The annual rate of stroke and systemic embolism was 2.12% in the rivaroxaban group and 2.42% in the warfarin group (HR = 0.88; 95% CI = 0.74 to 1.03; p = 0.001 for non-inferiority and p = 0.117 for superiority).
• No reduction in ischemic stroke.
This presentation is the intellectual property of the author.Contact them for permission to reprint and/or distribute.
Dias et al. Am J Nephrol. 43: 229-236, 2016.
This presentation is the intellectual property of the author.Contact them for permission to reprint and/or distribute.
Phase III Trial Comparison
RE-LY ROCKET-AF
ARISTOTLE ENGAGE AF-TIMI 48
Drug Dabigatran Rivaroxaban Apixaban Edoxaban
Dose (mg)
Frequency
150, 110
BID
20 (15*)
QD
5 (2.5*)
BID
60*, 30*
QD
N 18,113 14,266 18,206 >21,000
Design PROBE 2x blind 2x blind 2x blind
AF Criteria AF x 1
< 6 months
AF x 2
(>1 in <30 d)
AF or AFl x 2
< 12 months
AF x 1
< 12 months
% VKA naïve 50% 38% 43% 40% goal
RELY Dabigatran 110 mg
Dabigatran 150 mg
Warfarin
CHADS2 Mean0-1 (%)2 (%)3+ (%)
2.132.634.732.7
2.232.235.232.6
2.130.937.032.1
ROCKET -AF Rivaroxaban Warfarin
CHADS2 Mean2 (%)3 (%)4 (%)5 (%)6 (%)
3.5134329132
3.5134428122
ARISTOTLE Rivaroxaban Warfarin
CHADS2 Mean0-1 (%)2 (%)3+ (%)
2.134
35.830.2
2.134
35.830.2
This presentation is the intellectual property of the author.Contact them for permission to reprint and/or distribute.
RE-LY ROCKET AF ARISTOTLE
Time in Therapeutic Range (TTR)
64%67% warfarin-experienced
61% warfarin-naïve
Mean 55%Median 58%
Mean 62%Median 66%
RE-LYDabigatran 110 mg 1.53% per yearDabigatran 150 mg 1.11% per yearWarfarin 1.69% per year
ROCKET AFRivaroxaban 20mg 1.7% per yearWarfarin 2.2% per year
ARISTOTLEApixaban 5 mg 1.27% per yearWarfarin 1.60% per year
Primary Endpoint of Stroke or Systemic Embolism: Non-Inferiority Analysis
Antithrombotic Therapy RecommendationsClass I
• Selection of antithrombotic therapy should be based on the risk of thromboembolism irrespective of whether the AF pattern is paroxysmal, persistent, or permanent.
• In patient with nonvalvular AF, the CHA2DS2-VASc score is recommended for assessment of stroke risk.
This presentation is the intellectual property of the author.Contact them for permission to reprint and/or distribute.
Antithrombotic Therapy RecommendationsClass I
• For patient with mechanical heart valves, warfarin is recommended.
• For patients with nonvalvular HF with prior stroke, TIA, or a CHA2DS2-VASc score of 2 or greater, oral anticoagulants are recommended (warfarin: level of evidence A; dabigatran, rivaroxaban, or apixaban: level of evidence B).
Antithrombotic Therapy RecommendationsClass I
• For patients with nonvalvular AF unable to maintain a therapeutic INR level with warfarin, use of a direct thrombin inhibitor or factor Xainhibitor is recommended.
• For patients with atrial flutter, antithrombotic therapy is recommended according to the same risk profile used for AF.
This presentation is the intellectual property of the author.Contact them for permission to reprint and/or distribute.
Antithrombotic Therapy Recommendations
• Class IIa– For patients with nonvalvular AF and a
CHA2DS2-VASc score of 0, it is reasonable to omit antithrombotic therapy.
• Class IIb– For patients with nonvalvular AF and a
CHA2DS2-VASc score of 1, no antithrombotic therapy or treatment with an oral anticoagulant or aspirin may be considered.
Antithrombotic Therapy RecommendationsCKD
• Class I– Renal function should be evaluated prior to
initiation of direct thrombin or factor Xainhibitors and should be re-evaluated as needed and at least annually.
• Class IIa– For patients with nonvalvular AF with a
CHA2DS2-VASc score of ≥ 2 and who have ESRD (CrCl < 15) or are on HD, it is reasonable to prescribe warfarin.
This presentation is the intellectual property of the author.Contact them for permission to reprint and/or distribute.
Dose Selection in CKD
Renal Function Warfarin Dabigatran Rivaroxaban Apixaban
Normal/mild
impairment
Dose adjusted for
INR 2.0‐3.0
150 mg bid
(CrCl > 30)
20 mg qd with evening meals
(CrCl > 50)
5 or 2.5 mg bid (unless 2 of
3:
age > 80,
weight < 60 kg,
Cr > 1.5)
Moderate impairment 15 mg qd
(CrCl 30‐50)
Severe impairment 75 mg bid
(CrCl 15‐30)
15 mg qd
(CrCl 15‐30)
End‐stage but not on
Dialysis
May be continued
(CrCl < 15)
May be continued
(CrCl < 15)
May be continued
(CrCl < 15)
End‐stage but on
dialysis
Antithrombotic Therapy RecommendationsClass III – No Benefit
• Dabigatran and rivaroxaban are not recommended in patients with AF and end-stage CKD or on hemodialysis b/c of lack of evidence from clinical trials.
• Dabigatran should not be used in patients with AF and a mechanical heart valve.
This presentation is the intellectual property of the author.Contact them for permission to reprint and/or distribute.
Table from McCullough et al. Clin J Am SocNephrol. 11: 2079-2084, 2016.
Data from Kaatzet al. Stroke. 45: 2497-2505, 2014.
Back to Our Patient…
• 76 yo female with CHF, HTN, DM, ESRD, prior CVA, and CAD
• Patient had a major GIB requiring blood transfusion while in therapeutic range on warfarin
• She had a recurrent GIB on a NOAC
• She has a history of unsteady gait and prior falls
This presentation is the intellectual property of the author.Contact them for permission to reprint and/or distribute.
Non-Medication Options for Thromboembolism
Prophylaxis
Surgical Excision of Left Atrial Appendage
This presentation is the intellectual property of the author.Contact them for permission to reprint and/or distribute.
AtriCure AtriClip® LAA Occlusion System
Antithrombotic Therapy RecommendationsClass IIb
• Surgical excision of the LAA may be considered in patients undergoing cardiac surgery (level of evidence: C).
This presentation is the intellectual property of the author.Contact them for permission to reprint and/or distribute.
Percutaneous Left Atrial Appendage Closure Techniques
ev3 PLAATO ® System
This presentation is the intellectual property of the author.Contact them for permission to reprint and/or distribute.
Boston Scientific WATCHMAN® Device
St. Jude Medical Amplatzer® Cardiac Plug
This presentation is the intellectual property of the author.Contact them for permission to reprint and/or distribute.
SentreHeart LARIAT® Suture Delivery Device
Status of Available Devices
• The surgical AtriClip device was FDA-approved since 2009 and is currently the most widely used LAA exclusion device placed through an epicardial approach.
• The Lariat device received 510K clearance by the FDA for tissue approximation but not LAA exclusion and has been the target of some criticism due to procedural safety concerns, incomplete closure rates, and lack of stroke prevention data.
This presentation is the intellectual property of the author.Contact them for permission to reprint and/or distribute.
Status of Available Devices
• The Watchman device was shown to be noninferior to warfarin for stroke prevention in nonvalvular atrial fibrillation, and this device has gained approval from the FDA following lengthy delays and two randomized studies (PROTECT AF and PREVAIL).
Prospective Randomized Evaluation of the Watchman Left Atrial Appendage Closure Device in Patients with Atrial
Fibrillation Versus Long-Term Warfarin TherapyThe PREVAIL Trial
• LAA occlusion was noninferior to warfarin for ischemic stroke prevention or systemic embolism >7 days post-procedure.
• Noninferiority was not achieved for overall efficacy, but event rates were low and numerically comparable in both arms.
• Procedural safety has significantly improved, and the trial provides additional data that LAA occlusion is a reasonable alternative to warfarin therapy for stroke prevention in patients with NVAF who do not have an absolute contraindication to short-term warfarin therapy.
This presentation is the intellectual property of the author.Contact them for permission to reprint and/or distribute.
This presentation is the intellectual property of the author.Contact them for permission to reprint and/or distribute.
Summary
• Atrial fibrillation is a prevalent disease in patients with end stage renal disease and carries a significant risk for thromboembolic events.
• There is considerable debate on the risk-benefit profile of using warfarin in patients with atrial fibrillation on dialysis.
• Direct oral anticoagulants and new surgical and percutaneous approaches to left atrial appendage closure are options with great potential, but there is a lack of data in patients with ESRD.
• A new era of treatment options in this difficult patient population is now here.